Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

A technology-driven biopharma company focused on discovering and developing medicines.

4565 | T

Overview

Corporate Details

ISIN(s):
JP3431300007
LEI:
Country:
Japan
Address:
港区赤坂9−7−2

Description

Nxera Pharma Co., Ltd. (formerly Sosei Group Corp.) is a technology-driven biopharmaceutical company focused on the discovery and early development of novel medicines. The company utilizes its proprietary StaR® technology and world-leading expertise in G protein-coupled receptor (GPCR) structure-based drug design (SBDD) to create therapeutics for diseases with high unmet medical needs. By integrating advanced science and technology, Nxera Pharma develops its internal pipeline and collaborates with partners to accelerate the creation of life-changing treatments for patients worldwide. Its mission is to invest in science and technology to accelerate the development of these medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 08:40
訂正有価証券届出書(参照方式)
Japanese 42.6 KB
2025-12-12 08:39
訂正有価証券届出書(参照方式)
Japanese 42.6 KB
2025-12-05 08:21
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-12-05 08:20
訂正有価証券届出書(参照方式)
Japanese 41.9 KB
2025-08-08 09:06
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 09:05
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 08:57
確認書
Japanese 8.4 KB
2025-08-08 08:55
半期報告書-第36期(2025/01/01-2025/12/31)
Japanese 287.5 KB
2025-04-16 08:57
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:55
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:53
訂正有価証券届出書(参照方式)
Japanese 39.8 KB
2025-04-16 08:51
臨時報告書
Japanese 32.4 KB
2025-03-26 08:42
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:41
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:40
訂正有価証券届出書(参照方式)
Japanese 40.4 KB

Automate Your Workflow. Get a real-time feed of all Nxera Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nxera Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nxera Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.